Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3664643 | 0.84 | KDM4E (0.39) | PDE4APDE4BPDE4CPDE4DNOS1 | |
| SCHEMBL1012169 | 0.81 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DNQO2 | |
| SCHEMBL2840944 | 0.80 | SMN1; SMN2 (0.45) | NQO2CYP3A4CYP2D6HTR2ACACNA1H | |
| SCHEMBL2269491 | 0.78 | ADORA1 (0.50) | PDE4APDE4BPDE4CPDE4DNQO2 | |
| SCHEMBL5062073 | 0.76 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DNQO2 | |
| SCHEMBL8328517 | 0.74 | PKM (0.41) | PDE4APDE4BPDE4CPDE4DNQO2 | |
| SCHEMBL2841387 | 0.72 | L3MBTL4 (0.38) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2543790 | 0.72 | L3MBTL4 (0.38) | PDE4APDE4BPDE4CPDE4DNOS1 | |
| SCHEMBL2840584 | 0.71 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL5924181 | 0.71 | NQO2 (0.42) | NQO2CYP3A4KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | PDE4A 1507/4885PDE4B 1164/4885PDE4C 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.